News
IKT
1.670
+3.09%
0.050
Weekly Report: what happened at IKT last week (0601-0605)?
Weekly Report · 1d ago
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks · 6d ago
Weekly Report: what happened at IKT last week (0525-0529)?
Weekly Report · 06/01 09:12
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
TipRanks · 05/26 10:36
Weekly Report: what happened at IKT last week (0518-0522)?
Weekly Report · 05/25 09:12
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 05/19 12:20
Inhibikase Therapeutics (IKT) Gets a Buy from Cantor Fitzgerald
TipRanks · 05/19 12:20
Weekly Report: what happened at IKT last week (0511-0515)?
Weekly Report · 05/18 09:12
LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks · 05/16 14:35
Analysts Are Bullish on These Healthcare Stocks: Milestone Scientific (MLSS), Inhibikase Therapeutics (IKT)
TipRanks · 05/15 13:30
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks · 05/15 09:50
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
TipRanks · 05/14 06:02
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and PepGen Inc. (PEPG)
TipRanks · 05/13 14:30
Inhibikase Therapeutics GAAP EPS of -$0.10 beats by $0.01
Seeking Alpha · 05/12 20:54
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Benzinga · 05/12 20:37
*Inhibikase Therapeutics 1Q Loss/Shr 10c >IKT
Dow Jones · 05/12 20:03
INHIBIKASE THERAPEUTICS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACTIVITY
Reuters · 05/12 20:01
Press Release: Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Dow Jones · 05/12 20:01
Press Release: Inhibikase Therapeutics Announces -2-
Dow Jones · 05/12 20:01
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
TipRanks · 05/12 16:31
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).